Adrenocorticotropic Hormone [ACTH] Market to surpass US$ 1.91 Bn by 2031

Understanding Care Patterns of High Risk Patients Gains Importance During COVID-19 Pandemic

The entire U.S. healthcare system is planning, preparing, and collaborating to manage the COVID-19 pandemic. In order to maintain continuous supply chains, manufacturers in the adrenocorticotropic hormone (ACTH) market are striving to understand care patterns of high-risk patients and those with respiratory diseases. Manufacturers are establishing robust supply chains with urgent care centers, retail clinics in pharmacies, and workplace clinics to keep economies running during the pandemic. Since emergency departments are already stretched thin, these sites can act like wetlands to help absorb part of the overflow of patients with or without illnesses.

Get the sample copy of report@ https://qyresearchmedical.com/sample/111793

Telehealth services is emerging as a new business model for stakeholders in the adrenocorticotropic hormone (ACTH) market. These services are found to be most effective first line of access for non-elderly Americans with mild illness or with a risk of COVID-19.

Side Effects of ACTH Require Management by Healthcare Providers

The adrenocorticotropic hormone (ACTH) market is expected to surpass US$ 1.91 Bn by 2031. However, possible side effects of ACTH such as bone loss, indigestion, and muscle weakness are causing concerns among patients, pertaining to corticotropin as parenteral solution for injection. Hence, manufacturers are working closely with healthcare providers to create awareness about the management of side effects.

ACTH is being made available online for screening of patients presumed to have adrenocortical insufficiency. The growing incidence of stress and anxiety among individuals is acting as a key driver of the market, since stress may increase ACTH secretion in the body. On the other hand, ACTH is being used therapeutically as a drug to treat multiple sclerosis and infantile spasms.

High Prevalence of Cushing’s Disease, Hypopituitarism Creating Revenue Opportunities

ACTH blood tests are used in conjunction with cortisol tests to help detect, diagnose, and monitor conditions associated with excessive or deficient cortisol. The high prevalence of Cushing’s disease, Cushing syndrome, Addison disease, and hypopituitarism are contributing to the growth of the adrenocorticotropic hormone (ACTH) market, which is slated to clock a CAGR of 3.9% during the forecast period.

Measuring both cortisol and ACTH can help to differentiate different health conditions since the level of ACTH normally changes in the opposite direction to the level of cortisol. Since too much cortisol can lead to health issues such as acne, obesity, red face, and the likes, such findings are generating revenue opportunities for stakeholders in the adrenocorticotropic hormone (ACTH) market.

Abnormal Test Results, Ectopic Production of ACTH Influencing Market Growth

Individuals with insufficient cortisol production may exhibit symptoms including fatigue, diarrhea, and increased skin pigmentation. Such health issues are increasing revenue flow in the adrenocorticotropic hormone (ACTH) market. While ACTH is used to diagnose adrenal insufficiency, the ACTH stimulation test is being preferred for diagnosis. However, taking certain medications including oral, steroid or topical may cause abnormal results. Awareness is being created about the shortcomings of ACTH stimulation tests and management techniques are being implemented to avoid abnormal test results.

In addition to excess of ACTH from the pituitary gland, it can also generate from elsewhere in the body. This medical condition is known as ectopic production of ACTH, which is generated from tumors in different parts of the body.

Analysts’ Viewpoint

Trust-based relationships are gaining prominence during the COVID-19 pandemic, which involve reliable community organizations educating patients about precautions to be taken during the ongoing pandemic situation. Conditions such as ectopic ACTH syndrome (EAS) and non-neoplastic hypercortisolemia (NNH) tend to exhibit glucocorticoid resistance. Such findings are creating value-grab opportunities for companies in the adrenocorticotropic hormone (ACTH) market. It has been found that corticotropin as a parenteral solution for injection can lead to possible side effects including back pain, menstrual irregularities, and hyperpigmentation. Hence, stakeholders in the adrenocorticotropic hormone (ACTH) market should work closely with clinicians and healthcare providers to increase awareness about effective management of side effects to improve patient outcomes.

Adrenocorticotropic Hormone (ACTH) Market: Overview

The global adrenocorticotropic hormone (ACTH) market for the historical period of 2017–2019 and forecast period of 2021–2031, multiple clinical applications and rise in prevalence of various chronic diseases are projected to drive the global adrenocorticotropic hormone (ACTH) market

According to the report, the global adrenocorticotropic hormone (ACTH) market was valued at US$ 1.3 Bn in 2020 and is anticipated to expand at a CAGR of 3.9% from 2021 to 2031

Multiple Applications, Rise in Prevalence of Various Chronic Diseases to Drive Global Market

Corticotropin is used to treat conditions such as nephrotic syndrome (NS), rheumatology-related conditions, multiple sclerosis (MS), ankylosing spondylitis (AS), and infantile spasms (IS)

H.P. Acthar Gel was Questcor Pharmaceuticals, Inc.’s primary corticotropin product, which was acquired by Mallinckrodt in August 2014. The U.S. FDA approved Acthar for the treatment of 19 indications.

The rate of infantile spasm is estimated to be 2.5 to 6.0 per 10,000 live births. Its prevalence rate is 1.5 to 2.0 per 10,000 children aged 10 years or younger, based on data published in the National Organization for Rare Disorders, Inc. Rise in cases of target diseases and application of corticotropin in various indications drive the global adrenocorticotropic hormone (ACTH) market.

Increase in Investment in Research & Development

Demand for development of newer and technologically enhanced products is rising globally, owing to the treatment efficiency of drugs. Hence, major players operating in the market invest in research & development programs in order to develop new drugs.

Current oral glucocorticoid replacement therapy for patients with adrenal insufficiency (AI) does not truly mimic the normal physiologic cortisol rhythm, a nadir at bedtime, and gradually rising levels to the early morning peak between 3 am and 6 am before waking

Continuous subcutaneous hydrocortisone infusion therapy administered via an insulin pump to deliver hydrocortisone is another novel method of treatment of ACTH deficiency

Pexacerfont, a corticotropin-releasing hormone-1 (CRH1) receptor antagonist, is currently under investigation for the treatment of generalized anxiety disorder. Recent research has linked the activation of CRH1 receptor with euphoric feelings that accompany alcohol consumption. A CRH1 receptor antagonist developed by Pfizer, CP-154,526, is under investigation for the potential treatment of alcoholism.

Rise in investment in research & development by key players is likely to boost the growth of the global market during the forecast period

High Cost of Treatment in U.S. to Restrain Adrenocorticotropic Hormone (ACTH) Market

ACTH is priced higher than other agents, at around US$ 30,000 per vial. H.P. Acthar Gel, which cost around US$ 50 in 2000, was selling for US$ 28,000 for a 5 ml vial in 2012.

In February 2015, Questcor Pharmaceuticals, which acquired the rights to market Synacthen Depot, raised its price from US$ 35.66 to US$ 801.19 per vial. The cost of the required six-week treatment skyrocketed from about US$ 750 to nearly US$ 17,000. Questcor reportedly increased the price of its best-selling drug Acthar Gel by 85,000%, from US$ 50 in 2000 to US$ 34,000 per vial in 2017.

Adrenocorticotrophic hormone (ACTH) and prednisone are both used to treat infantile spasms (IS). However, the cost of ACTH injection is more than 100 times the cost of oral prednisolone.

These diseases are life-threatening and do not have a permanent cure; hence, the cost of lifelong treatment renders it unaffordable, leading to decline in the number of patients preferring to avail the treatment

Adrenocorticotropic Hormone (ACTH) Market: Competition Landscape

This report profiles major players in the global adrenocorticotropic hormone (ACTH) market based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments

The adrenocorticotropic hormone (ACTH) market is highly consolidated, with the presence of a few large players in international markets and few small players in regional markets. The top four to five players hold majority share of the global adrenocorticotropic hormone (ACTH) market.

Prominent players operating in the global adrenocorticotropic hormone (ACTH) market include

• Mallinckrodt plc
• Pfizer, Inc.
• Novartis AG
• Merck KGaA
• Ferring B.V.
• Avantor, Inc.
• Viatris, Inc.
• Hikma Pharmaceuticals plc

The report on the global adrenocorticotropic hormone (ACTH) market discusses individual strategies, followed by company profiles of adrenocorticotropic hormone (ACTH) providers. The competition landscape section has been included in the global adrenocorticotropic hormone (ACTH) market report to provide readers with a dashboard view of key market players operating in the global adrenocorticotropic hormone (ACTH) market.

Adrenocorticotropic Hormone (ACTH) Market: Key Developments

In July 2021, Mallinckrodt announced inclusion of Acthar Gel (repository corticotropin injection) in New European Respiratory Society (ERS) Treatment Guidelines for patients with pulmonary sarcoidosis

In June 2021, Avantor, Inc., a leading global provider of mission-critical products and services to customers in the life sciences, advanced technologies, and applied materials industries, announced it has completed its previously announced acquisition of Ritter GmbH and its affiliates

In March 2021, Mallinckrodt announced the U.S. Food and Drug Administration (FDA) approval for the updated Acthar Gel (repository corticotropin injection) label

In August 2020, Upsher-Smith Laboratories, LLC (Upsher-Smith) and AmbioPharm, Inc. (AmbioPharm) announced that the companies entered into a partnership agreement to develop and market Corticotropin Injection in the U.S.

In China, a research study on the role of corticotropin releasing factor in the neuroimmune mechanisms of depression is underway. This study was supported by the National Natural Science Foundation of China, the FHS Internal Collaboration Proposals 2017, the University of Macau, and the Science and Technology Development Fund (FDCT) of Macao.

Key Questions Answered in Adrenocorticotropic Hormone (ACTH) Market Report

• What is the scope of growth for companies in the global adrenocorticotropic hormone (ACTH) market?
• What will be the Y-o-Y growth of the global adrenocorticotropic hormone (ACTH) market between 2019 and 2027?
• What is the influence of changing trends in technologies on the global adrenocorticotropic hormone (ACTH) market?
• Will North America continue to be the most profitable market for adrenocorticotropic hormone (ACTH) providers?
• Which factors will hamper the growth of the global adrenocorticotropic hormone (ACTH) market during the forecast period?
• Which are the leading companies in the global adrenocorticotropic hormone (ACTH) market?

Adrenocorticotropic Hormone (ACTH) Market – Segmentation

Source

• Natural
• Synthetic

Indication

• Rheumatology
• Neurology
• Nephrotic Syndrome
• Ophthalmology
• Others

Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Purchase Complete Report Now@ https://qyresearchmedical.com/report/checkout/111793/2900